Clinical trial
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With…
NCT00494871 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00494871 |
|---|---|
| Title | Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation |
| Official title | Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation |
| Lead sponsor | Bayer, Industry |
| Collaborators | Janssen R&D, L.L.C. |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | Rivaroxaban (Xarelto, BAY59-7939), Warfarin, Rivaroxaban placebo, Warfarin placebo |
| Enrollment | 1,280 |
| Start date | Jun 1, 2007 |
| Primary completion | Dec 1, 2009 |
| Completion | Jan 1, 2010 |
| First posted | Jul 2, 2007 |
| Last update posted | Apr 20, 2015 |
| Countries | Japan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: